Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease

Heng Cao; Jiao Huang; Jie Chang; Yaqin Zhu; Junyu Liang; Chuanyin Sun; Jin Lin

doi:10.2478/jtim-2022-0029

Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease

J Transl Int Med. 2022 Nov 15;11(1):46-56. doi: 10.2478/jtim-2022-0029. eCollection 2023 Mar.

Authors

Heng Cao¹, Jiao Huang², Jie Chang³, Yaqin Zhu⁴, Junyu Liang¹, Chuanyin Sun¹, Jin Lin¹

Affiliations

¹ Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
² Department of Rheumatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
³ Department of Rheumatology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
⁴ Department of Traditional Chinese Medicine, Haining People Hospital, Haining 314499, Zhejiang Province, China.

Abstract

The idiopathic inflammatory myopathies (IIMs) are a group of connective tissue diseases that afect multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the most common and heterogeneous complication of IIMs, with its degree ranging from mild to fatal. Thus, it is critical to identify clinical features and validated biomarkers for predicting disease progression and prognosis, which could be beneficial for therapy adjustment. In this review, we discuss predictors for rapid progression of IIM-ILD and propose guidance for disease monitoring and implications of therapy. Systematic screening of myositis-specific antibodies, measuring serum biomarker levels, pulmonary function tests, and chest high-resolution computer tomography will be beneficial for the evaluation of disease progression and prognosis.

Keywords: biomarker; idiopathic inflammatory myopathies; interstitial lung disease; prognosis; rapid progressive.